Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $15.8 million.

  • China Pharma Holdings' Liabilities and Shareholders Equity rose 1737.15% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.7 million, marking a year-over-year decrease of 283.27%. This contributed to the annual value of $14.9 million for FY2024, which is 960.38% down from last year.
  • Latest data reveals that China Pharma Holdings reported Liabilities and Shareholders Equity of $15.8 million as of Q3 2025, which was up 1737.15% from $13.8 million recorded in Q2 2025.
  • China Pharma Holdings' 5-year Liabilities and Shareholders Equity high stood at $22.6 million for Q4 2021, and its period low was $13.5 million during Q3 2024.
  • Its 5-year average for Liabilities and Shareholders Equity is $16.9 million, with a median of $16.2 million in 2022.
  • Per our database at Business Quant, China Pharma Holdings' Liabilities and Shareholders Equity plummeted by 2148.2% in 2022 and then skyrocketed by 1737.15% in 2025.
  • China Pharma Holdings' Liabilities and Shareholders Equity (Quarter) stood at $22.6 million in 2021, then decreased by 21.48% to $17.8 million in 2022, then decreased by 7.39% to $16.5 million in 2023, then dropped by 9.6% to $14.9 million in 2024, then increased by 6.16% to $15.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $15.8 million for Q3 2025, versus $13.8 million for Q2 2025 and $14.2 million for Q1 2025.